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A B S T R A C T
Purpose: To compare imaging features of pancreatic metastases (PM) with those of pancreatic ductal adeno-
carcinomas (PDAC).
Methods: CT and MR scans of 24 patients with 54 PM and 30 patients with PDAC were reviewed to evaluate the
imaging features, which were compared by using a Chi square test.
Results: We found a statistically signiﬁcant diﬀerence between PM and PDAC based on location (P < 0.001),
margins (P < 0.001), arterial enhancement (P=0.004), rim enhancement (P < 0.001), pancreatic duct dila-
tation (P=0.01), common bile duct dilatation (P=0.003), vascular involvement (P=0.02), parenchymal
atrophy (P < 0.001), peripancreatic ﬂuid (P=0.03).
Conclusion: Imaging features might be helpful to diﬀerentiate PM from PDAC.
1. Introduction
Pancreatic malignancies are mainly primary exocrine pancreatic
neoplasms, whereas neuroendocrine tumors are much less common [1].
Secondary pancreatic neoplasms are rare, accounting from 2% to 5% of
all malignant lesions of the pancreas [2]. As demonstrated by autopsy
series, one third of pancreatic metastases (PM) are clinically mis-
diagnosed as primary malignancies [3]. Indeed, these lesions have no
speciﬁc symptoms and usually occur in advanced stage neoplasms,
when the clinical picture is already severe. Nevertheless, the pancreas
may be the only secondary site of a neoplasm, especially in renal cell
carcinoma [4], and the early diagnosis of PM may change the treatment
and prognosis of the disease. In the diﬀerential diagnosis of pancreatic
lesions, cancer antigens have limited diagnostic reliability [5].
Imaging modalities such as Computed Tomography (CT) and Magnetic
Resonance (MR) are routinely performed during the follow-up of onco-
logic patients [6–10]. In this setting CT and MR may play a crucial role in
the early identiﬁcation of PM, but their part in the management of PM has
been evaluated only on small series of patients [11–19].
Thus, the aims of our study were: (i) to review the CT and MR scans
performed on patients with PM at our Institution to describe the ima-
ging features of these lesions; (ii) to compare imaging features of PM
with those of pancreatic ductal adenocarcinomas (PDAC).
2. Materials and methods
2.1. Patients
We performed a search of our Institution database to identify all
cases of PM found on CT and MR scans from 2006 to 2016. The in-
clusion criterion was the presence of PM conﬁrmed by histology or by
follow-up examinations on patients receiving chemotherapy treat-
ments. We excluded those cases with direct pancreatic invasion by a
neoplasm from an adjacent organ. On the basis of this selection, our
study population consisted of 24 patients (12 males, 12 females; mean
age: 61, range 52–83). Six patients had two CT examinations, 12 pa-
tients had three CT examinations, 6 patients had 4 CT examinations. In
addition to CT, 13 patients had MR examinations (8 patients had one
MR and 5 patients had 2 MRs). Therefore we reviewed 90 examinations
(72 CT and 18 MR). Follow-up CT imaging was available in all patients
(mean 25months, range 4–33months) while follow-up MR imaging
was available in ﬁve patients (mean 8months, range 3–17months).
Moreover, we reviewed the CT and MR examinations performed on 30
patients (12 males, 18 females; mean age: 73, range 47–95) with his-
tologically conﬁrmed PDAC.
This retrospective study was approved by the Institutional Review
Board with a waiver of the requirement for informed consent.
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2.2. CT protocol
Patients underwent CT scan with a 64-slice CT scanner (Brilliance
64, Philips Medical System, Cleveland, Ohio, USA) and 128-slice CT
scanner (Deﬁnition AS+, Siemens Healthcare, Forchheim, Germany).
All patients drank 500–800ml of water immediately before undergoing
imaging to distend the stomach and duodenum. Unenhanced images of
the pancreas initially were obtained by using 3mm collimation to
deﬁne the cranio-caudal extent of the pancreas. Then, by using dual
head-power automatic injector (Stellant, MedRAD, Pittsburgh, PA,
USA) connected to an 18-gauge needle cannula placed in an antecubital
vein, a bolus of 100–120ml of non-ionic iodinated contrast agent
(Iomeprol, Iomeron 400, Bracco, Milan, Italy) followed by a saline
ﬂushing of 20–30ml was administered at an injection rate of 3–4ml/s.
For dynamic phase imaging, pancreatic parenchymal, portal and late
phases, were performed following a scanning delay of 23 s, 57 s and
163 s, respectively, after the attenuation of a region-of-interest posi-
tioned in the aorta at the level of the celiac trunk reached 100 HU. The
acquisition parameters were: tube voltage, 120 kV; collimation, 64/
128× 0.6mm; rotation time, 0.5 s; pitch, 0.6.
2.3. MR protocol
All patients were imaged with a 1.5T-MR imaging unit (Signa
Excite, General Electric, Health care, Milwaukee, WI, USA). A dedicated
abdominal multichannel surface coil was used for all patients. Imaging
protocol included axial pre-contrast images acquired with T2-weighted
fast-spin echo sequence (TR/TE, 4000/76ms; section thickness
5–6mm) and T1-weighted axial in-phase and out-of-phase gradient-
recalled-echo (GRE) sequence (TR/TE, 140/2.2–4.4 ms; section thick-
ness, 5–6mm). Those examinations performed for the evaluation of
pancreatic lesions included two-dimensional and three-dimensional MR
cholangiography sequences. Dynamic studies were performed with
three-dimensional fat-suppressed T1-weighted GRE sequence (LAVA-
TR/TE, 3.8/1.2 ms; FA 12; slice thickness: 4.4 mm; intersection gap
2mm; FOV: 44 cm; matrix 256×256) using a bolus-tracking system.
Images were acquired in the axial plane immediately before and after
intravenous injection of either 0.1 mmol/kg body weight of gadobenate
dimeglumine at 2ml/s or 0.025mmol//kg body weight of gadoxetic
acid at 1ml/s through a 20-gage intravenous catheter by means of a
power injector (Medrad Spectris Solaris EP MR Injection System; Bayer
Healthcare), followed by a 20-ml saline ﬂush at the same injection rate.
Scanning delays after automatic detection of contrast bolus were 18, 60,
180 s and 300 s, respectively, for the acquisition of the arterial, portal
venous, 3-min, and 5-min phase. The choice of contrast agent was based
on availability and personal preferences of the radiologist. Finally, all
patients underwent diﬀusion-weighted imaging sequence as follow:
single-shot spin-echo echo-planar with chemical-shift selective fat-
suppression technique; scan direction, axial; respiration, non–breath-
hold method; b value, 0 s/mm2, 150 s/mm2 and 600 s/mm2 (with dif-
fusion weighted gradients applied in three orthogonal directions); TR/
TE, 8000/73ms; inversion time, 70ms; matrix, 128×64; slice thick-
ness/gap, 5mm/0mm; ﬁeld of view, 40 cm; number of excitations, 6;
and acquisition time, approximately 5min.
2.4. Image interpretation and statistical analysis
CT and MR images were independently reviewed by two radi-
ologists with 16 and 9 years of experience in oncology imaging, re-
spectively. Disagreements were resolved by consensus. Since the his-
tologic conﬁrmation of PM was available in few cases, the
morphological and size changes of these lesions detected during treat-
ment was used as proof of their nature. In patients with PM, we assessed
the location of primary malignancies and the presence of extra-pan-
creatic metastases. Then, in both patients with PM and those with
PDAC, the following imaging features were evaluated: site, number,
size, margins, density/signal intensity of lesions and healthy par-
enchyma on non-contrast and contrast enhanced images, signal in-
tensity on high b-value DWI images, enhancement pattern on arterial
(hypovascular/hypervascular) and venous phase (homogeneous/het-
erogeneous), rim enhancement, calciﬁcations, main pancreatic duct
dilatation (> 2.5mm), common bile duct dilatation (> 7mm), vascular
involvement, atrophic parenchyma, peripancreatic ﬂuid, pancreatitis.
The Chi square test was used to compare the imaging features of PM
Table 1
Distribution of primary malignancies and extra-pancreatic metastases of 24
patients with pancreatic metastases.
Site Number (%)
Primary malignancy
Lung carcinoma 8/24 (33%)
Renal cell carcinoma 6/24 (25%)
Thyroid cancer 4/24 (17%)
Breast carcinoma 2/24 (8%)
Merkeloma cancer 2/24 (8%)
Adrenal gland cancer 1/24 (4%)
Soft tissue liposarcoma 1/24 (4%)
Extra-pancreatic metastases
Lung 18/24 (75%)
Lymph nodes 14/24 (58%)
Liver 12/24 (50%)











Imaging features of 54 pancreatic metastases and 30 primary pancreatic adenocarci-
nomas.
Imaging characteristics Metastases Adenocarcinoma P-value
Size (range) 2.5 cm (1.2–4.3) 4.7 cm (1–9.4)
Location < 0.001
Head 6/54 (11%) 17/30 (57%)
Neck 6/54 (11%) 2/30 (7%)
Body 20/54 (37%) 6/30 (20%)
Tail 22/54 (41%) 5/30 (17%)
Margins < 0.001
Well-deﬁned 21/54 (39%) 0/30 (0%)
Ill-deﬁned 19/54 (35%) 23/30 (77%)
Lobulated 14/54 (26%) 7/30 (23%)
Attenuation on unenhanced CT 0.344
Hypodense 23/54 (43%) 16/30 (53%)
Isodense 31/54 (57%) 14/30 (47%)
Hyperdense 0/54 (0%) 0/30 (0%)
Enhancement on arterial phase 0.004
Hypovascular 38/54 (70%) 29/30 (97%)
Hypervascular 16/54 (30%) 1/30 (3%)
Enhancement on venous phase 0.057
Homogeneous 15/54 (28%) 3/30 (10%)
Heterogeneous 39/54 (72%) 27/30 (90%)
Rim enhancement 22/54 (41%) 1/30 (3%) < 0.001
Calciﬁcations 2/54 (4%) 3/30 (10%) 0.835
Main pancreatic duct dilatation 6/54 (11%) 18/30 (60%) 0.01
Common bile duct dilatation 3/54 (6%) 15/30 (50%) 0.003
Vascular involvement 7/54 (13%) 18/30 (60%) 0.02
Parenchymal atrophy 3/54 (6%) 17/30 (57%) < 0.001
Peripancreatic ﬂuid 4/54 (7%) 13/30 (43%) 0.003
Pancreatitis 0/54 (0%) 2/30 (7%) 0.197
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and PDAC. A P-value<0.05 was considered statistically signiﬁcant.
Statistical analysis was performed using SPSS 20.0 software.
3. Results
A total of 24 patients were positive for PM in our study based on
consensus review. We found a total of 54 metastatic lesions to the
pancreas. In these patients, the primary malignancy was lung carci-
noma in 8/24 (33%), followed by renal cell carcinoma in 6/24 (25%).
At the time of the detection of PM, 18/24 patients (75%) had metas-
tases to other organs. The location of primary malignancies and extra-
pancreatic metastases are shown in Table 1.
Six patients had synchronous PM at the time of the initial diagnosis
of the primary tumor. In 18 patients PM was diagnosed during follow-
up imaging, after an average of 18months from the initial staging
evaluation. PM were most commonly multiple (13/24 patients, 54%),
followed by solitary (9/24, 38%) and diﬀuse (2/24, 8%). In our series,
13 patients with PM and 12 with PDAC underwent MR in addition to
CT. In all cases, both PM and PDAC had low signal intensity on T1-
weighted images, intermediate signal intensity on T2-weighted images,
and high signal intensity on high b-value DWI images. The additional
features of PM and PDAC are shown in Table 2.
We found a statistically signiﬁcant diﬀerence between PM and
PDAC on the basis of location (χ2= 20.3, P < 0.001), margins
(χ2= 18.3, P < 0.001), enhancement on arterial phase (χ2= 8.3,
P=0.004), rim enhancement (χ2= 13.6, P < 0.001), pancreatic duct
dilatation (χ2= 6.6, P=0.01), common bile duct dilatation (χ2= 8.4,
P=0.003), vascular involvement (χ2= 5.1, P=0.02), parenchymal
atrophy (χ2= 11.1, P < 0.001), and peripancreatic ﬂuid (χ2= 4.4,
P=0.03). Conversely, no signiﬁcant diﬀerences were found on the
basis of appearance on unenhanced CT, portal phase enhancement,
pancreatitis, calciﬁcations, MR appearance on T1 weighted, T2
weighted, and DWI images.
Among PM, 9/24 patients (37%) had solitary pancreatic lesions, of
which in six cases were the only sites of metastatic spread of disease. On
arterial phase, they were hypervascular in 4/9 lesions (44%) compared
to the normal enhanced pancreas; in 3/9 lesions (33%), we found a
peripheral rim enhancement on the venous phase. Intratumoral calci-
ﬁcations were found in 1 case (11%). Pancreatic duct dilatation was
noted in 1 case (11%), while common bile duct dilatation, vascular
involvement, and parenchymal atrophy were not demonstrated in any
case.
Figs. 1–6 show some representative cases from our study popula-
tion.
4. Discussion
Although PM are rare, their diagnosis should be suspected when a
pancreatic lesion is detected in a patient with a history of malignancy.
In our study, the most frequent primary malignancies that metastasized
Fig. 1. Thoracoabdominal CT of a ﬁfty-ﬁve year old woman with liposarcoma of the thigh. Axial portal phase CT scan images (A–B) show multiple fat-containing lung metastases (arrows,
A) and a fat-containing pancreatic metastasis (arrow, B). Note also the pericardial eﬀusion (curved arrow, A).
Fig. 2. Abdominal MR scan of a 52-year-old woman with
breast carcinoma and isolated pancreatic metastasis.
Arterial phase fat-saturated volumetric T1-weighted image
(A) shows a small hypovascular metastasis in the head of
the pancreas (arrow). Portal (B) and late (C) phase fat-sa-
turated volumetric T1-weighted images show persistent
hypointensity of pancreatic metastasis (arrow). The b0 (D)
and b600 (E) diﬀusion-weighted images show slight hy-
perintensity of the pancreatic metastasis (arrow), which
demonstrates restricted pattern of diﬀusion on ADC map
(F).
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to the pancreas were lung cancer and renal cell carcinoma, in line with
previous studies [20]. PM may be recognized during the initial imaging
staging, at routine follow-up or when imaging is performed for speciﬁc
signs or symptoms, such as jaundice or abdominal pain [20,21]. PM are
commonly associated with disseminated disease and poor prognosis;
indeed, a median survival of 8.7months has been reported in the lit-
erature [22]. However, there may be a long latency period between the
diagnosis of the primary tumor and the appearance of PM. Minni et al.
reported that 77.6% of patients developed PM metachronously at an
average interval of 9.2 years after the diagnosis of the primary tumor
[11]. In these cases in particular, CT and MR might help to diﬀerentiate
a PM from a second primary pancreatic tumor. In our study, PM were
more frequently multiple with well-deﬁned margins and showed vari-
able behavior after contrast injection, rare vascular involvement, par-
enchymal atrophy, and pancreatic or bile ducts dilatation. Moreover,
we found a statistically signiﬁcant diﬀerence between PM and PDAC on
the basis of location, margins, enhancement on arterial phase, rim en-
hancement, pancreatic duct dilatation, common bile duct dilatation,
vascular involvement, parenchymal atrophy, and peripancreatic ﬂuid.
There are three patterns of PM described in the literature: solitary
metastasis, multiple metastases, and diﬀuse involvement. Although in
our study the multiple pattern was slightly more frequent than the
single pattern, the latter, characterized by a localized and well-deﬁned
mass, was the most common in previous studies [12]. The multiple
pattern is characterized by the presence of more than a single lesion and
has been previously reported in 5%–10% of cases. The diﬀuse pattern is
characterized by diﬀuse enlargement of the pancreas with an in-
ﬁltrative mass; it has been reported in 15%–44% of cases [12–15]. It is
well known that PDAC most commonly involves the pancreatic head, as
also shown in our series. Conversely, our results showed PM had no
predilection for a particular segment of the pancreas, in line with pre-
vious studies [23]. On unenhanced CT most PM were hypo- or iso-
attenuating to normal pancreatic parenchyma, with no signiﬁcant dif-
ferences with PDAC. Calciﬁcations and cystic degeneration are other
ﬁndings which can be observed in PM on unenhanced CT [16]. Simi-
larly, no signiﬁcant diﬀerences between PM and PDAC were observed
on unenhanced MR images. PM and PDAC were always hypointense in
comparison with the normal high signal of normal gland tissue on un-
enhanced T1-weighted images, both with and without fat saturation
[22]. On T2-weighted and high b-values diﬀusion-weighted images, the
lesions were slightly heterogeneous and moderately hyperintense [12].
Some authors reported that PM from renal cell carcinoma may show
intracellular lipid which can be identiﬁed through chemical shift MR as
a drop of signal on out-of-phase images [24]. Nevertheless, in our series
we did not observe this sign in any of our cases. Following intravenous
contrast media injection, the behavior of PM may be variable. Smaller
lesions (< 1.5 cm) may be hypervascular as compared with the normal
parenchyma, while larger lesions (> 1.5 cm) may show peripheral
Fig. 3. Abdominal CT scan of a 71-year-old man with clear cell renal cell carcinoma and isolated pancreatic metastasis. Axial unenhanced (A), pancreatic parenchymal (B), portal (C) and
late (D) phases CT images, demonstrate a metastasis in the uncinate process of the pancreas (curved arrow). The lesion shows the same enhancement of the primary left kidney renal cell
carcinoma (arrow).
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enhancement with central low attenuation/hypointensity mainly due to
necrosis; most other lesions are usually hypovascular [25–27]. In our
series, most PM were hypovascular and most showed heterogeneous
enhancement on the venous phase. Moreover, a frequent feature of PM
was rim enhancement, observed in 41% of cases. Conversely, only one
patient (3%) with PDAC showed rim enhancement after contrast in-
jection. Peripheral enhancement has been previously described as a
typical feature of PM, especially from renal cell carcinoma, and can be
used to diﬀerentiate them from PDAC [28]. As reported by Low et al.,
this sign is related to the fact that PM parasitize blood supply from
surrounding structures, thereby receiving greater perfusion in the per-
iphery of the lesion than in the center [28]. The diﬀerential diagnoses
of hypervascular PM are primary pancreatic neuroendocrine tumor,
intrapancreatic accessory spleen, and vascular lesions such as arter-
iovenous ﬁstulas or aneurysms of the splenic artery [27,29,30]. Isolated
PM from renal cell carcinoma may occur after a long disease free in-
terval [23,31], especially from the clear cell type of primary tumor, and
should be diﬀerentiated from primary pancreatic endocrine tumor,
which may be an incidental ﬁnding on cross sectional imaging. Indeed,
large non-functional pancreatic neuroendocrine tumors may be
asymptomatic for a long time, while small functional neuroendocrine
tumors may develop symptoms secondary to hormone secretion [32].
Kanga TW et al. evaluated the usefulness of contrast-enhanced CT with
perfusion imaging [33]. They concluded that tumor multiplicity and
relative percentage washout value of tumor enhancement with a spe-
ciﬁc cut-oﬀ of 19% could be helpful for diﬀerentiating PM of renal cell
carcinoma from hypervascular pancreatic endocrine tumors [33]. The
diﬀerential diagnoses of hypovascular PM are primary pancreatic car-
cinoma, lymphomas, and focal pancreatitis. As shown in our and pre-
vious studies, it is possible to diﬀerentiate PM from PDAC, because
PDAC is often associated with other features, including dilatation of the
upstream pancreatic duct and/or bile ducts, pancreatic parenchymal
atrophy, and mesenteric/splenic vessel involvement [1,19]. Conversely,
as demonstrated by our results, these features are less commonly as-
sociated with PM. Indeed, in solitary PM pancreatic duct dilatation was
rare, while common duct dilatation was not observed. Neither vascular
involvement nor parenchymal atrophy was encountered in a case of
solitary PM. Furthermore, it is important to emphasize that a history of
Fig. 4. Abdominal MR scan of a 71-year-old woman with primary pancreatic adenocarcinoma. MR cholangiogram image (A) shows common bile duct dilatation (arrow) and main
pancreatic duct dilatation (arrowhead). Coronal T2-weighted fast spin echo image (B) shows common bile duct dilatation (arrow). Three-dimensional fat-suppressed T1-weighted
gradient echo image (C) shows a small primary pancreatic adenocarcinoma in the head of the pancreas (arrow). Axial fat-suppressed T2-weighted fast spin echo image (D) shows common
bile duct dilatation (arrow) and main pancreatic duct dilatation (arrowhead). The b600 diﬀusion-weighted image (E) shows slight hyperintensity of the pancreatic primary pancreatic
adenocarcinoma (arrow), which demonstrates restricted pattern of diﬀusion on ADC map (F).
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malignancy and evaluation of previous imaging are helpful to make a
correct diagnosis, with biopsy in controversial cases.
Our study had some limitations. Our study was retrospective and
our patient population was relatively small. Secondly, our study had
pathologic proof of PM in only six patients. However, these limitations
appear inevitable when dealing with a disease as rare as PM.
Fig. 5. Abdominal CT scan of a 44-year-old woman with lung carcinoma and pancreatic metastases. Axial portal phase CT images demonstrate two metastases in the tail (A, arrows) and
one metastasis in the head (B, arrow). The lesions show the typical rim enhancement and well-deﬁned margins, with neither pancreatic and bile ducts dilatation nor vascular invasion nor
parenchymal atrophy.
Fig. 6. Abdominal CT scan of a 70-year-old woman with primary pancreatic adenocarcinoma. Axial portal phase CT images demonstrate a hypovascular lesion of the head of the pancreas
with ill-deﬁned margins (A–B–C, arrow), associated with main pancreatic duct dilatation (C, curved arrow), bile ducts dilatation (A–B–C–D, arrowheads), and atrophy of the body of the
pancreas (C). Note also the involvement of the inferior mesenteric vein, which is narrowed (A–B, hollow arrow).
M. Galia et al. Clinical Imaging 51 (2018) 76–82
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5. Conclusions
In conclusion, PM are rare lesions, in our series most commonly seen
in patients with lung cancer and renal cell carcinoma. Accurate diag-
nosis of these lesions may be challenging and biopsy is often required to
achieve the correct diagnosis. Imaging features might be helpful to
diﬀerentiate PM from PDAC. However, the oncological history and





All procedures performed in studies involving human participants
were in accordance with the ethical standards of the institutional and/
or national research committee and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards. For this type
of study formal consent is not required.
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